Homology Medicines (FIXX) got here out with a quarterly lack of $0.67 per share versus the Zacks Co
Homology Medicines (FIXX) got here out with a quarterly lack of $0.67 per share versus the Zacks Consensus Estimate of a lack of $0.58. This compares to lack of $0.40 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -15.52%. 1 / 4 in the past, it was anticipated that this gene enhancing firm would submit a lack of $0.54 per share when it really produced a lack of $0.61, delivering a shock of -12.96%.
During the last 4 quarters, the corporate has not been in a position to surpass consensus EPS estimates.
Homology Medicines, which belongs to the Zacks Medical – Generic Medication business, posted revenues of $0.44 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 17.60%. This compares to year-ago revenues of $0.95 million. The corporate has topped consensus income estimates simply as soon as during the last 4 quarters.
The sustainability of the inventory’s instant value motion based mostly on the…